Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Flying Brands completes acquisition of Imaging Biometrics

"We are pleased to have found partners who not only understand the technology we have developed but also the path to commercialisation of the applications of that technology," said IB's CEO, Michael Schmainda
Medical imaging
"Our strategy to establish Flying Brands as a leading provider of convenient, cost-effective and clinically superior treatment to patients suffering from kidney stones, cancer and strokes based on proven technologies, will move forward significantly with this acquisition," said CEO, Trevor Brown

Medical services and software company Flying Brands Limited (LON:FBDU) has pulled the trigger on its proposed acquisition of Imaging Biometrics.

The company is paying US$68,134 in cash and issuing 11mln shares to the vendor, though there is an option for Flying Brands to pay a cash equivalent of 4p a share in lieu of issuing shares.

READ: Flying Brands confirms advanced talks regarding a North American medical imaging acquisition

Imaging Biometrics (IB) is based in Wisconsin, USA. It is advancing the field of medical imaging by specialising in the design and manufacture of advanced visualisation software solutions using quantitative imaging endpoints/biomarkers.

IB has been managing the CE marking and US Food and Drug Administration (FDA) clearance process for StoneChecker, Flying Brands’ kidney stone medical imaging software; FDA clearance is expected before the end of June this year.

The launch of StoneChecker in the USA will include targeting of the existing luminary sites in which IB has established its IB Clinic product, and marketing resources will be combined to target the same customer group of board-certified radiologists at both tertiary and regional hospitals. Initially, Flying Brands will focus on the commercialisation of artificial intelligence software for the management of kidney and brain diseases, which both share similar patient management and reimbursement pathways and affect large numbers of patients each year.

IB is also involved in the rapidly growing radiology artificial intelligence (AI) market by offering a full range of services, including medical discovery, proof of concept testing, contract manufacturing, clinical evaluation of biomarkers, regulatory clearance and full commercialisation of approved products, Flying Brands noted.

WATCH: StoneChecker goes ahead with 'game-changing' acquisition of Imaging Biometrics

This provides Flying Brands with multiple opportunities to facilitate the growing interest in AI solutions in radiology and positions it well for future industry consolidation, the company proclaimed.

“North America is the largest medical market in the world and … the acquisition of IB provides not only immediate access to that territory but also to a very high level of technical expertise for the development of new products and services,” said Trevor Brown, the chief executive officer of Flying Brands.

“IB's management team are well known to us and share our vision of introducing disruptive technology - that will change cost models - to fast-growing cancer and stroke treatment markets," he added.

The shares were up 1.1% at 4.05p in the first hour of trading on Tuesday.

View full FBDU profile View Profile

Flying Brands Ltd Timeline

Related Articles

H&T Pawnbrokers store
July 02 2018
Last year the company saw gross profits jump 45% thanks to a booming personal loan book and robust sales of luxury second-hand watches and jewellery.
Flying Brands
July 17 2018
“We look forward to the future with confidence and excitement," said Flying Brands boss Trevor Brown.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use